Efficacy of tacrolimus plus narrowband ultraviolet B phototherapy versus narrowband ultraviolet B phototherapy alone in the treatment of vitiligo
DOI:
https://doi.org/10.66344/jpad.v27i3.927Keywords:
Efficacy, Tacrolimus, Narrow Band, Vitiligo.Abstract
Objective To compare the efficacy of tacrolimus plus narrowband ultraviolet B (NB-UVB) phototherapy versus NB-UVB phototherapy alone in the treatment of vitiligo .
Methods A total of 94 patients were randomized into two equal groups A and B. Patients in group A were managed with combined treatment i.e. NB-UVB three times a week plus topical tacrolimus 0.1% once daily application while patients in group B will be subjected to NB-UVB alone three times a week alone for three months. The efficacy was determined in term of repigmentation by measuring vitiligo area severity score.
Results 41 (87.2%) patients in group A achieved efficacy while group B showed efficacy in 32 (68.1%) patients (p=0.022). Efficacy was unrelated to age, sex, severity and duration of vitiligo.
Conclusion Combination therapy is more effective than monotherapy in the treatment of vitiligo.
References
1. Berti S, Buggiani G, Lotti T. Use of Tacrolimus ointment in vitiligo alone or in combination therapy. Skin Ther Letter. 2009;19:4.
2. Szczurko O, Heather S. A systematic review of natural health product treatment for vitiligo. Br J Dermatol. 2008;8:2.
3. Garg BJ, Saraswat A , Bhatia A, Katare OP. Topical treatment in vitiligo and the potential uses of new drug delivery systems. Indian J Dermatol Venereol Leprol. 2010;76:231-8.
4. Wazir SM, Paracha MM, Khan SU. Efficacy and safety of topical mometasone furoate 0.01% vs. tacrolimus 0.03% and mometasone furoate 0.01%in vitiligo. J Pak Assoc Dermatol. 2010;20:89-92.
5. Yaghoobi R, Omidian M, Bagherani N. Comparison of therapeutic efficacy of topical corticosteroids and oral zinc sulphate-topical corticosteroid combination in the treatment of vitiligo patients. BMC Dermatol. 2011;11:7.
6. Nordal EJ, Guleng GE, Ronnevig JR. Treatment of vitiligo with narrowband-UVB (TL01) combined with tacrolimus ointment (0.1%) vs. placebo ointment, a randomized right ⁄ left double-blind comparative study. J Eur Acad Dermatol Venereol. 2011;25:1440-3.
7. Berti S, Buggiani G, Lotti T. Use of tacrolimus ointment in vitiligo alone or in combination therapy. Skin Ther Letter. 2013;18:7.
8. Pacifico A, Leone G. Photo (chemo)therapy for vitiligo. Photodermatol Photoimmunol Photomed. 2011;27:261-77.
9. Majid I. Vitiligo management: An update. BJMP. 2010;3:332.
10. Tamler C, Estrada BD, Oliveira PA, Avelleir JC. Tacrolimus 0.1% ointment in the treatment of vitiligo. An Bras Dermatol. 2011;86:1.
11. Bacigalupi, Robert M, Ann D, Ronald S. Evidence-based, non-surgical treatments for vitiligo. Am J Clin Dermatol. 2012;13;217-37.
12. Review article Topical tacrolimus: A boon to dermatology Research Drops Pharma. InterScience Int J Pharm Biomed Sci. 2012;3:188-92.
13. Falabella R, Barona MI. Update on skin repigmentation therapies in vitiligo. Pigment Cell Melanoma. 2008;17:42-65.
14. Gawkrodger DJ, Ormerod AD, Shaw L, Mauri-Sole I, Whitton ME, Watts MJ et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol. 2008;159:1051-76.
15. Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, González U. Interventions for vitiligo. Cochrane Database Syst Rev. 2010;1:CD003263.
16. Fai D, Cassano N, Vena GA. Narrowband UVB phototherapy combined with tacrolimus ointment in vitiligo: a review of 110 patients. J Eur Acad Dermatol Venereol. 2007;21:916-20.
17. Mehrabi D, Pandya AG. A randomized, placebo-controlled, double-blinded trial comparing narrowband UV-B plus 0.1% tacrolimus ointment with narrowband UV-B plus placebo in the treatment of generalized vitiligo. Arch Dermatol. 2006;142:927-9.
18. Hanifin JM, Ling MR, Langley R. Tacrolimus Ointment Study Group. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol. 2001;44 (suppl):S28-38.
19. Paller A, Eichenfield LF, Leung DYM. Tacrolimus Ointment Study Group. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2001;44 (suppl):S47-57.
20. Reitamo S, Rissanen J, Remitz A. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol. 1998;111:396-8.
21. Soter NA, Fleischer AB Jr, Webster GF. Tacrolimus Ointment Study Group. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol. 2001;44 (suppl):S39-46.
22. Kang S, Lucky AW, Pariser D. Tacrolimus Ointment Study Group. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol. 2001;44 (suppl):S58-64.
23. Lepe V, Moncada B, Castanedo-Cazares JP. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol. 2005;139:893-6.
24. Dawid M, Veensalu M, Grassberger M, Wolff K. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: Results of a randomized, double-blind, vehicle-controlled study. J Dtsch Dermatol Ges. 2006;4:942-6.
25. Castanedo-Cazares JP, Lepe V, Moncada B. Repigmentation of chronic vitiligo lesions by following tacrolimus plus ultraviolet B-narrow-band. Photodermatol Photoimmunol Photomed. 2003;19:35-6.
26. Nordal EJ, Guleng GE, Ronnevig JR. Treatment of vitiligo with narrowband-UVB(TL01) combined with tacrolimus ointment (0.1%) vs. placebo ointment, a randomized right/left double blind comparative study. J Eur Acad Dermatol Venereol. 2011;25:1440-3.
27. Mehrabi D, Pandya AG. A randomized, placebo-controlled, double-blind trial comparing narrowband UV-B plus 0.1% tacrolimus ointment with narrowband UV-B plus placebo in the treatment of generalized vitiligo. Arch Dermatol. 2006;142:927-9.
28. Klahan S, Asawanonda P. Topical tacrolimus may enhance repigmentation with targeted narrowband ultraviolet B to treat vitiligo: A randomized, controlled study. Clin Exp Dermatol. 2009;34:e1029-3.
Downloads
Published
Issue
Section
License
Copyright (c) 2018 Ghafoor Ullah, Somaiya Rehman, Sahibzada Mehmood Noor, Muhammad Majid Paracha
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
